Annovis Bio, Inc.

The Parkinson’s field is littered with clinical failures and another candidate, UCB’s minzasolmin, is the latest to fall in the quest for a disease modifying treatment. The Belgium-based group has i

S.Biomedics’ stem cell therapy for Parkinson’s disease has shown positive results in an assessment of one-year data from the three patients (first low-dose cohort) in a Phase I/IIa clinical trial, rai

Following the recent miss in its Alzheimer’s disease trial of buntanetap, Annovis Bio, Inc. really needed a hit in its pivotal trial of the same drug in Parkinson’s. On 2 July, it said it had seen p

More mid-stage clinical trial failures are piling up in the Parkinson’s disease space, with the latest disappointment coming from South Korea's Bukwang Pharmaceutical Co., Ltd. , underlining the diff